DZ Bank’s AbCellera Biologics ABCL Stock Holding History

DZ Bank’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,300	Closed	-$5.98K	–	937
2024 Q3	$5.98K	Hold	2,300	–	–	﹤0.01%	970
2024 Q2	$6.81K	Hold	2,300	–	–	﹤0.01%	1001
2024 Q1	$10.4K	Hold	2,300	–	–	﹤0.01%	1009
2023 Q4	$13.1K	Hold	2,300	–	–	﹤0.01%	975
2023 Q3	$10.6K	Hold	2,300	–	–	﹤0.01%	965
2023 Q2	$14.9K	Hold	2,300	–	–	﹤0.01%	977
2023 Q1	$17.3K	Hold	2,300	–	–	﹤0.01%	998
2022 Q4	$23.3K	Hold	2,300	–	–	﹤0.01%	989
2022 Q3	$22.7K	Hold	2,300	–	–	﹤0.01%	983
2022 Q2	$24.5K	Sell	2,300 -3,700	-62%	-$31.3K	﹤0.01%	985
2022 Q1	$58.5K	Sell	6,000 -6,000	-50%	-$56.8K	﹤0.01%	940
2021 Q4	$172K	Buy	12,000 +6,000	+100%	+$91K	﹤0.01%	968
2021 Q3	$120K	Hold	6,000	–	–	﹤0.01%	880
2021 Q2	$132K	Hold	6,000	–	–	﹤0.01%	865
2021 Q1	$204K	Hold	6,000	–	–	﹤0.01%	783
2020 Q4	$247K	Buy	+6,000	New	+$274K	﹤0.01%	743

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

DZ Bank's ABCL Position: Q4 2024 in Review

DZ Bank sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 2,300 shares — an estimated $5.98K sold.

DZ Bank first reported a position in ABCL in Q4 2020 and held it in 16 quarters. The position peaked at $247K in Q4 2020. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

DZ Bank reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
DZ Bank sold 2,300 AbCellera Biologics shares in Q4 2024, an estimated $5.98K.
DZ Bank first reported a position in AbCellera Biologics in Q4 2020 and held it in 16 quarters.
DZ Bank's AbCellera Biologics position peaked at $247K in Q4 2020.
146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on DZ Bank's 13F filing for Q4 2024, filed 14 Feb 2025.